While CD138 and CD45 are standard markers in PC characterization and clinical diagnosis, BCMA is a newly described clonal B-cell and PC marker of great interest in hematological malignancies [7,10], conferring this assay with broader capability for detecting and characterizing terminal PCs, plasmablasts, and post-GC B cells. Here, SDC1 is linked to hematologic disorder.